Swiss Pharmaceutical Giant to Launch 16 New Clinical Trials in 2026
Roche, a prominent Swiss pharmaceutical company, is set to continue its commitment to clinical research in Mexico with an investment of approximately 1,200 million pesos (around $57,000,000 USD) for the period 2025-2026. This investment aims to drive innovative scientific development and provide health solutions that enhance people’s lives while supporting equitable, sustainable, and high-quality healthcare systems.
Focus Areas for the New Clinical Trials
The new trials will cover various therapeutic areas, including solid and hematological tumors, cardiometabolic diseases, nephrology, rheumatology, neurosciences, hemophilia, ophthalmology, respiratory diseases, and infectious diseases. This diversification will benefit around 1,200 patients.
Roche’s Commitment to Decentralized Healthcare
Roche reaffirms its dedication to decentralizing healthcare, ensuring that the best diagnosis, treatment, and care reach everyone regardless of their location. This commitment is demonstrated through the inclusion of over 180 individuals in a phase II study for obesity treatment, with phase III to be conducted in 2026.
Roche’s Clinical Research Achievements in 2025
In 2025, Roche conducted 81 clinical trials across 22 Mexican states involving 1,400 patients. Notably, the company included more than 180 individuals in a phase II study for obesity treatment, with phase III to be developed this year.
New Treatment Options for High-Prevalence Diseases
In 2026, Roche will expand its portfolio with new treatments targeting chronic diseases, focusing on diabetes, ocular conditions, cancer, and multiple sclerosis.
- Cancer Treatments: Roche will introduce atezolizumab subcutaneous for lung cancer, triple-negative breast cancer, urothelial carcinoma, and hepatocellular carcinoma.
- Multiple Sclerosis Treatment: Ocrelizumab subcutaneous will be available for patients with remitting-relapsing and primary progressive multiple sclerosis, administered through a 10-minute injection given twice a year.
- Breast Cancer Innovation: Alongside its subcutaneous therapy for breast cancer, which reduces application time from hours to minutes, Roche will launch a new targeted therapy for locally advanced or metastatic HR+/HER2- breast cancer patients with PIK3CA mutation, present in approximately 40% of cases. This innovation includes a PCR diagnostic test to identify these patients and guide their treatment.
- Diabetes Monitoring: Roche will present Accu-Chek SmartGuide CGM, an AI-based continuous glucose monitoring device measuring levels every five minutes, detecting patterns, and predicting hypoglycemia risks up to 30 minutes in advance for more personalized control.
- Ophthalmology Advancements: Roche’s therapy for diabetic macular edema and age-related macular degeneration will receive a new indication for treating secondary macular edema caused by retinal vein occlusion, a condition that may lead to blurred vision or visual loss if not addressed promptly.
Key Questions and Answers
- What is Roche investing in Mexico? Roche is investing approximately 1,200 million pesos (around $57,000,000 USD) in clinical research for the period 2025-2026.
- How many new clinical trials will Roche launch in 2026? Roche plans to initiate 16 new clinical trials in 2026.
- What therapeutic areas will these new trials cover? The trials will focus on solid and hematological tumors, cardiometabolic diseases, nephrology, rheumatology, neurosciences, hemophilia, ophthalmology, respiratory diseases, and infectious diseases.
- What achievements has Roche accomplished in clinical research in Mexico? In 2025, Roche conducted 81 clinical trials across 22 states involving 1,400 patients and included over 180 individuals in a phase II study for obesity treatment.
- What new treatments will Roche introduce in 2026? Roche will launch new treatments for cancer, multiple sclerosis, breast cancer, diabetes, and ophthalmology conditions.
